tbuckley/cabot-search huggingface dataset:
Thyroid hormone treatment among pregnant women with subclinical hypothyroidism: US national assessment
Authors: Spyridoula Maraka, Raphael Mwangi, Rozalina G McCoy, Xiaoxi Yao, Lindsey R Sangaralingham, Naykky M Singh Ospina, Derek T O’Keeffe, Ana E Espinosa De Ycaza, Rene Rodriguez-Gutierrez, Charles C Coddington, Marius N Stan, Juan P Brito, Victor M Montori
Journal: BMJ (2017)

<b>Objective</b>&nbsp;To estimate the effectiveness and safety of thyroid hormone treatment among pregnant women with subclinical hypothyroidism. <b>Design</b>&nbsp;Retrospective cohort study. <b>Setting</b>&nbsp;Large US administrative database between 1 January 2010 and 31 December 2014. <b>Participants</b>&nbsp;5405 pregnant women with subclinical hypothyroidism, defined as untreated thyroid stimulating hormone (TSH) concentration 2.5-10 mIU/L. <b>Exposure</b>&nbsp;Thyroid hormone therapy. <b>Main outcome measure</b>&nbsp;Pregnancy loss and other pre-specified maternal and fetal pregnancy related adverse outcomes. <b>Results</b>&nbsp;Among 5405 pregnant women with subclinical hypothyroidism, 843 with a mean pre-treatment TSH concentration of 4.8 (SD 1.7) mIU/L were treated with thyroid hormone and 4562 with a mean baseline TSH concentration of 3.3 (SD 0.9) mIU/L were not treated (P&lt;0.01). Pregnancy loss was significantly less common among treated women (n=89; 10.6%) than among untreated women (n=614; 13.5%) (P&lt;0.01). Compared with the untreated group, treated women had lower adjusted odds of pregnancy loss (odds ratio 0.62, 95% confidence interval 0.48 to 0.82) but higher odds of preterm delivery (1.60, 1.14 to 2.24), gestational diabetes (1.37, 1.05 to 1.79), and pre-eclampsia (1.61, 1.10 to 2.37); other pregnancy related adverse outcomes were similar between the two groups. The adjusted odds of pregnancy loss were lower in treated women than in untreated women if their pre-treatment TSH concentration was 4.1-10 mIU/L (odds ratio 0.45, 0.30 to 0.65) but not if it was 2.5-4.0 mIU/L (0.91, 0.65 to 1.23) (P&lt;0.01). <b>Conclusion</b>&nbsp;Thyroid hormone treatment was associated with decreased risk of pregnancy loss among women with subclinical hypothyroidism, especially those with pre-treatment TSH concentrations of 4.1-10 mIU/L. However, the increased risk of other pregnancy related adverse outcomes calls for additional studies evaluating the safety of thyroid hormone treatment in this patient population.
Association of Disparities in Known Minor Histocompatibility Antigens with Relapse-Free Survival and Graft-Versus-Host-Disease Upon Allogeneic Stem Cell Transplantation,
Authors: Willemijn Hobo, Kelly Broen, Walter J.F.M. van der Velden, Annelies Greupink-Draaisma, Niken Adisty, Yannick Wouters, Michel G.D. Kester, Hanny Fredrix, Joop H. Jansen, Bert A. van der Reijden, J.H. Frederik Falkenburg, Theo de Witte, Frank W.M.B. Preijers, Anton Schattenberg, Ton Feuth, Nicole N.A. Blijlevens, Nicolaas Schaap, Harry Dolstra
Journal: Blood (2011)
Video Laryngoscopy in the Intensive Care Unit
Authors: Brian O’Gara, Samuel Brown, Daniel Talmor
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Expression of CD10 and CD7 Defines Distinct In Vivo Lymphoid Reconstituting Capacity within Human Cord Blood CD34+CD38-Cells.
Authors: Shuro Yoshida, Fumihiko Ishikawa, Leonard D. Shultz, Noriyuki Saito, Mitsuhiro Fukata, Kazuya Shimoda, Koichi Akashi, Mine Harada
Journal: Blood (2006)
Clinical Outcomes In Patients with Chronic Myelogenous Leukemia (CML) and the BCR-ABL 35 Base Pair (bp) Intron 8 Insertion Mutation.
Authors: Ellin Berman, Jorge Cortes, Hagop M. Kantarjian, Thomas O'Hare, Christopher Eide, Richard D. Press, Brian J Druker, Cyrus V. Hedvat
Journal: Blood (2010)
Letter to the Editor on the article “Clinical evaluation of balloon occlusion of the lower abdominal aorta in patients with placenta previa and previous cesarean section: A retrospective study on 43 cases.”: The drier the surgical field, the better?
Authors: Shigeki Matsubara, Hironori Takahashi, Yosuke Baba, Hiroyasu Nakamura
Journal: International Journal of Surgery (2017)
Surgical data science for next-generation interventions
Authors: Lena Maier-Hein, Swaroop S. Vedula, Stefanie Speidel, Nassir Navab, Ron Kikinis, Adrian Park, Matthias Eisenmann, Hubertus Feussner, Germain Forestier, Stamatia Giannarou, Makoto Hashizume, Darko Katic, Hannes Kenngott, Michael Kranzfelder, Anand Malpani, Keno März, Thomas Neumuth, Nicolas Padoy, Carla Pugh, Nicolai Schoch, Danail Stoyanov, Russell Taylor, Martin Wagner, Gregory D. Hager, Pierre Jannin
Journal: Nature Biomedical Engineering (2017)
Osteonectin/SPARC Is Epigenetically Silenced in AML with MLL Gene Rearrangements and Selectively Inhibits the Growth of MLL Rearranged Cell Lines.
Authors: Jorge F. DiMartino, Norman J. Lacayo, Marie Varadi, Yaddanapudi Ravindranath, Ron Yu, Branimir Sikic, Susana C. Raimondi, Gary V. Dahl
Journal: Blood (2004)
Irrational Exuberance: Cardiopulmonary Resuscitation as Fetish
Authors: Philip M. Rosoff, Lawrence J. Schneiderman
Journal: The American Journal of Bioethics (2017)

The Institute of Medicine and the American Heart Association have issued a "call to action" to expand the performance of cardiopulmonary resuscitation (CPR) in response to out-of-hospital cardiac arrest. Widespread advertising campaigns have been created to encourage more members of the lay public to undergo training in the technique of closed-chest compression-only CPR, based upon extolling the virtues of rapid initiation of resuscitation, untempered by information about the often distressing outcomes, and hailing the "improved" results when nonprofessional bystanders are involved. We describe this misrepresentation of CPR as a highly effective treatment as the fetishization of this valuable, but often inappropriately used, therapy. We propose that the medical profession has an ethical duty to inform the public through education campaigns about the procedure's limitations in the out-of-hospital setting and the narrow clinical indications for which it has been demonstrated to have a reasonable probability of producing favorable outcomes.
Rational Combination Treatment of a Novel Selective mTOR Kinase Inhibitor AZD8055 with IGF-1R Inhibitors in Multiple Myeloma
Authors: Diana Cirstea, Teru Hideshima, Loredana Santo, Homare Eda, Tyler A. Scullen, Neeharika Nemani, Anuj Mahindra, Andrew Yee, Yiguo Hu, Naoya Mimura, Jiro Minami, Hiroto Ohguchi, Rikio Suzuki, Francesca Cottini, Sylvie M Guichard, Kenneth C. Anderson, Noopur Raje
Journal: Blood (2012)
Gene Expression Profiling of Human Endothelial Progenitor Cells Differentiated from Peripheral Blood Mononuclear Cells.
Authors: Beatrice E. Gee, Jerry J. Manlove-Simmons, Yao Huang, Kwaku Asare, Adel Driss, Guoshen Wang, Leonard M. Anderson, Gary H. Gibbons
Journal: Blood (2007)
David Oliver: When are hospital doctors right to challenge patients’ families?
Authors: David Oliver
Journal: BMJ (2017)

I’ve written before here about the importance of actively involving hospital inpatients’ relatives—especially those who play vital and stressful roles as carers—and of ensuring timely and accessible conversations.1 Inadequate or insensitive communication lies behind many complaints.23

But doctors responsible for large numbers of inpatients in overstretched hospitals have obligations to balance. Our primary obligation to the patient is enshrined in professional codes.4 Then come obligations to all our patients, whether or not they have involved or questioning relatives. Time shouldn’t be skewed disproportionately towards a few families …
Pharmacokinetics (PK) of Lenalidomide When Administered Alone or in Combination with Dexamethasone in Chinese Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): The MM-021 Trial
Authors: Nianhang Chen, Dao-bin Zhou, Li Yu, Jay Mei, Liangang Liu, Xiaomin Wang, Honeylet Wortman-Vayn, Jian Hou
Journal: Blood (2012)
Exercise management in type 1 diabetes: a consensus statement
Authors: Michael C Riddell, Ian W Gallen, Carmel E Smart, Craig E Taplin, Peter Adolfsson, Alistair N Lumb, Aaron Kowalski, Remi Rabasa-Lhoret, Rory J McCrimmon, Carin Hume, Francesca Annan, Paul A Fournier, Claudia Graham, Bruce Bode, Pietro Galassetti, Timothy W Jones, Iñigo San Millán, Tim Heise, Anne L Peters, Andreas Petz, Lori M Laffel
Journal: The Lancet Diabetes & Endocrinology (2017)
The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment
Authors: Jason B. Williams, Brendan L. Horton, Yan Zheng, Yukan Duan, Jonathan D. Powell, Thomas F. Gajewski
Journal: The Journal of Experimental Medicine (2017)

Although the presence of tumor-infiltrating lymphocytes (TILs) indicates an endogenous antitumor response, immune regulatory pathways can subvert the effector phase and enable tumor escape. Negative regulatory pathways include extrinsic suppression mechanisms, but also a T cell-intrinsic dysfunctional state. A more detailed study has been hampered by a lack of cell surface markers defining tumor-specific dysfunctional TILs, and PD-1 alone is not sufficient. Recently, we identified the transcription factor Egr2 as a critical component in controlling the anergic state in vitro. In this study, we show that the Egr2-driven cell surface proteins LAG-3 and 4-1BB can identify dysfunctional tumor antigen-specific CD8
Low Activity of Cytochrome P450 1A2 (CYP1A2) Enzyme May Protect From Iron Accumulation in Children and Adults with Transfusion Depended β-Thalassemia Major
Authors: Shoshana Revel-Vilk, Itamar Nitzan, Ada Goldfarb, Nilla Hemed, Eyal Shteyer
Journal: Blood (2011)
A Common Deletion Polymorphism in the BIM Gene Contributes to Intrinsic Imatinib Resistance in Chronic Myelogenous Leukemia
Authors: Axel M Hillmer, King-Pan Ng, Charles Chuah, Wen Chun Juan, Tun-Kiat Ko, Audrey S.M. Teo, Pramila N Ariyaratne, Naoto Takahashi, Kenichi Sawada, Yao Fei, Wah Heng Lee, Weijie Huang, John C Allen, Xing Yi Woo, Niranjan Nagarajan, Vikrant Kumar, Anbupalam Thalamuthu, Wan Ting Poh, Ai Leen Ang, Hae Tha Mya, Gee Fung How, Li Yi Yang, Liang Piu Koh, Veera S Nadarajan, Wee-Joo Chng, Hein Than, Lay Cheng Lim, Yeow-Tee Goh, Markus M Nöthen, Tien Y Wong, Atif Shahab, Xiaoan Ruan, Valère Cacheux-Rataboul, Wing-Kin Sung, Yijun Ruan, S. Tiong Ong
Journal: Blood (2011)
Peer review report 2 on “Using the Hyperinsulinemic Euglycemic Clamp to Assess Insulin Sensitivity at 3 Months Following Roux-en-Y Gastric Bypass Surgery in Type 2 Diabetes Patients with BMI&lt;35 kg/m2 in China”
Authors: Süleyman Çetinkünar
Journal: International Journal of Surgery (2017)
Preclinical Pharmacokinetic and Metabolism of Apixaban, a Potent and Selective Factor Xa Inhibitor.
Authors: Kan He, Bing He, James E. Grace, Baomin Xin, Donglu Zhang, Donald J. Pinto, Joseph M. Luettgen, Robert M. Knabb, Patrick Y.S. Lam, Ruth R. Wexler, William G. Humphreys, Wen-Chyi Shyu, Scott J. Grossman
Journal: Blood (2006)
Molecular dissection of germline chromothripsis in a developmental context using patient-derived iPS cells
Authors: Sjors Middelkamp, Sebastiaan van Heesch, A. Koen Braat, Joep de Ligt, Maarten van Iterson, Marieke Simonis, Markus J. van Roosmalen, Martijn J. E. Kelder, Evelien Kruisselbrink, Ron Hochstenbach, Nienke E. Verbeek, Elly F. Ippel, Youri Adolfs, R. Jeroen Pasterkamp, Wigard P. Kloosterman, Ewart W. Kuijk, Edwin Cuppen
Journal: Genome Medicine (2017)

Germline chromothripsis causes complex genomic rearrangements that are likely to affect multiple genes and their regulatory contexts. The contribution of individual rearrangements and affected genes to the phenotypes of patients with complex germline genomic rearrangements is generally unknown. To dissect the impact of germline chromothripsis in a relevant developmental context, we performed trio-based RNA expression analysis on blood cells, induced pluripotent stem cells (iPSCs), and iPSC-derived neuronal cells from a patient with de novo germline chromothripsis and both healthy parents. In addition, Hi-C and 4C-seq experiments were performed to determine the effects of the genomic rearrangements on transcription regulation of genes in the proximity of the breakpoint junctions. Sixty-seven genes are located within 1 Mb of the complex chromothripsis rearrangements involving 17 breakpoints on four chromosomes. We find that three of these genes (FOXP1, DPYD, and TWIST1) are both associated with developmental disorders and differentially expressed in the patient. Interestingly, the effect on TWIST1 expression was exclusively detectable in the patient's iPSC-derived neuronal cells, stressing the need for studying developmental disorders in the biologically relevant context. Chromosome conformation capture analyses show that TWIST1 lost genomic interactions with several enhancers due to the chromothripsis event, which likely led to deregulation of TWIST1 expression and contributed to the patient's craniosynostosis phenotype. We demonstrate that a combination of patient-derived iPSC differentiation and trio-based molecular profiling is a powerful approach to improve the interpretation of pathogenic complex genomic rearrangements. Here we have applied this approach to identify misexpression of TWIST1, FOXP1, and DPYD as key contributors to the complex congenital phenotype resulting from germline chromothripsis rearrangements.
Cutaneous Nodules in the Genital Area in a Patient With Chronic Graft-vs-Host Disease
Authors: Yvonne Nguyen, Shaun Chou, Pablo Fernandez-Peñas
Journal: JAMA Dermatology (2017)

A woman with chronic graft-vs-host disease presented with several yellow-colored nodules, some of them ulcerated with extrusion of yellow-colored discharge, on the left labia majora and the perianal area. What is your diagnosis?
Bone Loss in Patients with Previously Untreated Lymphoma: The Effect of Periodontal Disease on the Use of Zoledronic Acid
Authors: Vince D. Cataldo, Michael A. Thompson, Bela B. Toth, Perpetua Sanjorjo, B. Nebiyou Bekele, Camilo Jimenez, William A. Murphy, Auris O. Huen, Rebecca B. Arbuckle, Michelle A. Fanale, Luis E. Fayad, Nathan Fowler, Larry W. Kwak, Peter W. McLaughlin, Sattva S. Neelapu, Barbara Pro, Alma Rodriguez, Jatin Shah, Fredrick B. Hagemeister
Journal: Blood (2008)
Myocarditis with Immune Checkpoint Blockade
Authors: Stéphane Ederhy, Anne-Laure Voisin, Stéphane Champiat
Journal: New England Journal of Medicine (2017)

Paton raises the thorny issue of attribution of primacy.We were aware of multiple observational studies indicating favorable outcomes with the use of antihypertensive agents in patients with malignant hypertension. 1 In reexamining the literature, we did indeed find an important trial involving patients with severe hypertension (diastolic blood pressure, >130 mm Hg) who were randomly assigned to antihypertensive therapy (with reserpine, chlorothiazide, or hydrochlorothiazide-guanethidine) or matching placebos. 2We will resist calling this the first trial and instead use the term "early."Shamy and Fedyk appropriately remind us that there are special situations in responsible clinical research in which informed consent may be waived.Their point was recently illustrated in the Informed Fresh versus Old Red Cell Management (INFORM) trial. 3In this trial, each site's ethics committee waived the need for patient consent "because all the patients received treatment that was consistent with the current standard of care." 3 We agree with their additional points indicating that obtaining consent is only one of the many responsibilities of investigators in conducting quality clinical investigation.
Donor CD34+ Cell Chimerism at Day 28 and Chronic Graft-Versus-Host Disease (GvHD) but Not High-Risk Cytogenetics Influence Outcome of Allogeneic Hematopoetic Cell Transplantation (HCT) Following Reduced Intensity Conditioning (RIC) in Patients with AML and MDS.
Authors: Haifa K. Al-Ali, Claudia Nehring, Rainer Krahl, Cornelia Becker, Sabine Leiblein, Jeanett Edelmann, Wolfram Poenisch, Thoralf Lange, Dietger Niederwieser
Journal: Blood (2006)
Coordinate Interstitial Deletion of Retinoblastoma (RB1) and Neurobeachin (NBEA) Is a Recurring Event in Multiple Myeloma.
Authors: Julie O’Neal, AnnaLynn Molitoris, Feng Gao, Anjum Hassan, Ryan Monahan, Samantha Barrios, Kathy Weilbaecher, Ravi Vij, Michael H. Tomasson
Journal: Blood (2007)
The Efficacy of Dual PI3K and mTOR Inhibitor, NVP-BEZ235 against BCR-ABL Positive Leukemia Cells Include ABL Kinase Domain Mutation in Combination with Nilotinib.
Authors: Seiichi Okabe, Tetsuzo Tauchi, Shinya Kimura, Taira Maekawa, Kazuma Ohyashiki
Journal: Blood (2009)
Comprehensive Evaluation of MicroRNA Genes and Gene Expression Using Next Generation Sequencing in a Patient with Acute Myelogenous Leukemia.
Authors: Giridharan Ramsingh, Dan C Koboldt, Todd A Fehniger, Todd Wylie, Vincent Magrini, Maria Trissal, Sunita Koul, Li-Wei Chang, Rakesh Nagarajan, Timothy J. Ley, Elaine Mardis, Daniel C. Link
Journal: Blood (2009)
Presence of Residual Thromboemboli at Least Six Months after a First Episode of Symptomatic Pulmonary Embolism: DO Perfusion Scintigraphy and CT-Angiography Agree?
Authors: Francesco Dentali, Marco Donadini, Benilde Cosmi, Alessandro Squizzato, Silvia Bozzato, Walter Ageno
Journal: Blood (2008)
Radiotherapy planning study comparing volumetric modulated arc therapy (VMAT) with intensity modulated radiotherapy (IMRT) in the treatment of bladder and pelvic lymph nodes.
Authors: Victoria Harris, Karole Warren-Oseni, Robert Anthony Huddart
Journal: Journal of Clinical Oncology (2012)

320 Background: VMAT is increasingly used as an alternative to IMRT and has been shown to reduce treatment time and monitor units delivered. We report a radiotherapy (RT) planning study of bladder and pelvic lymph node (LN) RT comparing dosimetric outcomes of VMAT and IMRT techniques. Methods: 8 patients with/at high risk of LN+ bladder cancer were treated with bladder/pelvic LN IMRT. 4 clinical target volumes (CTVs) were defined: Whole bladder (CTV1), Pelvic LN (CTV2), Involved Bladder (CTV3) and Involved LNs (CTV4). Margins were applied to create 4 corresponding PTVs. IMRT plans were compared with VMAT plans in order to assess planning target volume (PTV) and organ at risk (OAR) coverage. The same PTV/OAR volumes and doses were used for each technique. Results: The mean dose statistics were compared for each dosimetric parameter for both techniques. The Wilcoxon signed-rank test was used to compare techniques with statistical significance assumed as p&lt;0.05. Both techniques met prescription goals for PTV coverage. Comparison of conformity indices revealed no significant difference between techniques. VMAT achieved significantly better homogeneity in coverage of PTV2, although this finding was not replicated in the other PTVs (Table). Homogeneity index (HI) was defined as HI = 100x(D2-D98)/ Dp, where Dp = prescribed dose. VMAT resulted in significantly larger volumes of bowel (4.7%) and rectum (4.8%) receiving low dose radiation (15 Gy) than IMRT, although there was no significant difference seen at higher dose levels. Comparison with 3D conformal radiotherapy (3D-CRT) showed that both techniques resulted in a large reduction in bowel irradiation to 45Gy (IMRT = 123cc, VMAT = 145cc and 3D-CRT = 218cc). Conclusions: VMAT offers an attractive alternative to IMRT with similar conformality. Whilst increased low dose RT to OARs was seen with VMAT, it is of doubtful significance relative to the higher doses received by these structures. [Table: see text]
Novel Application of High-Dose-Rate Brachytherapy for Severe, Recalcitrant Acrodermatitis Continua of Hallopeau
Authors: Joanie Pinard, Ruth Ann Vleugels, Drew J. B. Kurtzman, Phillip M. Devlin, Mital Patel
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Minimal Disseminated Disease Is An Independent Poor Prognosis Marker Among High Risk Burkitt's Lymphoma Patients .
Authors: Lara Mussolin, Marta Pillon, Gloria Tridello, Maria Paola Boaro, Emanuele S d'Amore, Luca Lo Nigro, Salvatore Buffardi, Alessandra Lombardi, Alessandra Sala, Claudio Favre, Maurizio Aricò, Angelo Rosolen
Journal: Blood (2009)
The integrin PSI domain has an endogenous thiol isomerase function and is a novel target for antiplatelet therapy
Authors: Guangheng Zhu, Qing Zhang, Emily C. Reddy, Naadiya Carrim, Yunfeng Chen, Xiaohong Ruby Xu, Miao Xu, Yiming Wang, Yan Hou, Li Ma, Yan Li, Min Rui, Tania N. Petruzziello-Pellegrini, Christopher Lavalle, Tyler W. Stratton, Xi Lei, Reheman Adili, Pingguo Chen, Cheng Zhu, John A. Wilkins, Richard O. Hynes, John Freedman, Heyu Ni
Journal: Blood (2017)
BCR-ABL Fusion Transcript Do Not Significantly Influence the Outcome of Chronic Myeloid Leukemia Patients In Early Chronic Phase Treated with Imatinib Mesylate: a GIMEMA CML WP Analysis.
Authors: Fausto Castagnetti, Gabriele Gugliotta, Francesca Palandri, Massimo Breccia, Giorgina Specchia, Elisabetta Abruzzese, Tamara Intermesoli, Adele Capucci, Bruno Martino, Fabio Stagno, Patrizia Pregno, Marilina Amabile, Simona Soverini, Nicoletta Testoni, Giuliana Alimena, Giovanni Martinelli, Fabrizio Pane, Giuseppe Saglio, Michele Baccarani, Gianantonio Rosti
Journal: Blood (2010)
Modulation of Histone H3K4 and H3K27 Methylation Levels Via Pharmacological Inhibition of LSD1 and Degradation of the EZH2-Containing Polycomb Repressive Complex 2 Stimulates ATRA-Mediated Differentiation of AML Cells.
Authors: Kevin R. Petrie, Tino Schenk, Manuel Boix Chornet, Louise Howell, John E Dick, Victor E Marquez, Laurence J Marton, Patrick M Woster, Robert A Casero, Arthur Zelent
Journal: Blood (2009)
The Efficacy of Rabbit Antithymocyte Globulin (Thymoglobulin®) with Cyclosporin As First-Line Treatment in Aplastic Anemia,
Authors: Seung-Hwan Shin, Seung-Ah Yahng, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Hee-je Kim, Seok Lee, Chang-Ki Min, Seok-Goo Cho, Dong-Wook Kim, Woo-Sung Min, Chong-Won Park, Jong-Wook Lee
Journal: Blood (2011)